Background: On January 31, 2025, the UK’s National Health Service (NHS) approved exagamglogene autotemcel (Casgevy), a gene-editing therapy for severe sickle cell disease (SCD), at a cost of ￡1.65 million (approximately 1.287 billion CFA francs) per patient. Given SCD’s high prevalence in Cameroon, we aimed to explore public opinion in this context, identify common themes, and assess implications for healthcare equity. Methods: We conducted a qualitative thematic analysis of 712 comments from a single, highly engaged Facebook post identified using the search string “sickle cell Cameroon cure”. Comments, primarily in Pidgin English, were systematically translated into English by bilingual researchers (EEC and MBR) and coded using NVivo 14 to derive themes and sentiments. Manual cross-checking ensured coding consistency and reduced linguistic bias. The study adhered to the 32-item COREQ checklist. Results: Seven themes emerged: enthusiasm and appreciation, scepticism about cost, accessibility issues, advocating for genotype testing, scepticism about practical use, hopes for subsidies, and personal stories. Sentiment shifted from optimism to frustration due to the treatment’s cost, with many emphasising prevention through genotype testing over an unaffordable cure. While the approval of Casgevy elicits hope, its cost renders it inaccessible for most Cameroonians, exacerbating health inequities. Conclusion: The cure elicits optimism but is overshadowed by its cost, exacerbating inequities and emphasizing prevention. Subsidized testing and treatment are critical to meeting community needs. This study highlights social media as a lens for public health insights, especially in low-resource settings like Cameroon.
References
[1]
Grosse, S.D., Odame, I., Atrash, H.K., Amendah, D.D., Piel, F.B. and Williams, T.N. (2011) Sickle Cell Disease in Africa. American Journal of Preventive Medicine, 41, S398-S405. https://doi.org/10.1016/j.amepre.2011.09.013
[2]
Piel, F.B., Patil, A.P., Howes, R.E., Nyangiri, O.A., Gething, P.W., Dewi, M., et al. (2013) Global Epidemiology of Sickle Haemoglobin in Neonates: A Contemporary Geostatistical Model-Based Map and Population Estimates. The Lancet, 381, 142-151. https://doi.org/10.1016/s0140-6736(12)61229-x
[3]
Makani, J., Cox, S.E., Soka, D., Komba, A.N., Oruo, J., Mwamtemi, H., et al. (2011) Mortality in Sickle Cell Anemia in Africa: A Prospective Cohort Study in Tanzania. PLOS ONE, 6, e14699. https://doi.org/10.1371/journal.pone.0014699
[4]
Rees, D.C., Williams, T.N. and Gladwin, M.T. (2010) Sickle-Cell Disease. The Lancet, 376, 2018-2031. https://doi.org/10.1016/s0140-6736(10)61029-x
[5]
Thomson, A.M., McHugh, T.A., Oron, A.P., Teply, C., Lonberg, N., Vilchis Tella, V., et al. (2023) Global, Regional, and National Prevalence and Mortality Burden of Sickle Cell Disease, 2000-2021: A Systematic Analysis from the Global Burden of Disease Study 2021. The Lancet Haematology, 10, e585-e599.
[6]
Munung, N.S., Treadwell, M., Kamga, K.K., Dennis-Antwi, J., Anie, K., Bukini, D., et al. (2023) Caught between Pity, Explicit Bias, and Discrimination: A Qualitative Study on the Impact of Stigma on the Quality of Life of Persons Living with Sickle Cell Disease in Three African Countries. Quality of Life Research, 33, 423-432. https://doi.org/10.1007/s11136-023-03533-8
[7]
Quinn, C.T. and Ware, R.E. (2025) The Modern Use of Hydroxyurea for Children with Sickle Cell Anemia. Haematologica, 110, 1061-1073. https://doi.org/10.3324/haematol.2023.284633
[8]
Arlet, J., Bernaudin, F., Deme-Ly, I., Coulibaly, B., Corbasson, A., Diagne, I., et al. (2025) Use of Hydroxyurea in French-Speaking Sub-Saharan Africa. Annals of Hematology, 104, 937-941. https://doi.org/10.1007/s00277-024-06180-2
[9]
Brito, M., Ginete, C., Ofakunrin, A., Diaku-Akinwumi, I. and Inusa, B.P.D. (2025) Treating Sickle Cell Disease in Resource-Limited Sub-Saharan Africa: Recent Strategies and Recommendations in Addressing the Gaps for the Provision of Evidence-Based Management. Expert Review of Hematology, 18, 447-462. https://doi.org/10.1080/17474086.2025.2500599
[10]
Frangoul, H., Locatelli, F., Sharma, A., Bhatia, M., Mapara, M., Molinari, L., et al. (2024) Exagamglogene Autotemcel for Severe Sickle Cell Disease. New England Journal of Medicine, 390, 1649-1662. https://doi.org/10.1056/nejmoa2309676
[11]
Frangoul, H., Altshuler, D., Cappellini, M.D., Chen, Y., Domm, J., Eustace, B.K., et al. (2021) CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia. New England Journal of Medicine, 384, 252-260. https://doi.org/10.1056/nejmoa2031054
[12]
NHS England (2025) Revolutionary Gene-Editing Therapy for Sickle Cell ‘Offers Hope of a Cure’ for NHS Patients. https://www.england.nhs.uk/2025/01/revolutionary-gene-editing-therapy-for-sickle-cell/
[13]
The World Bank in Cameroon (2025) The World Bank’s Country Partnership Strategy in Cameroon Focuses on Increasing the Country’s Competitiveness and Improving Service Delivery. World Bank. https://www.worldbank.org/en/country/cameroon/overview
[14]
Freiermuth, C.E., Haywood, C., Silva, S., Cline, D.M., Kayle, M., Sullivan, D., et al. (2014) Attitudes toward Patients with Sickle Cell Disease in a Multicenter Sample of Emergency Department Providers. Advanced Emergency Nursing Journal, 36, 335-347. https://doi.org/10.1097/tme.0000000000000036
[15]
Jose, R., Narendran, M., Bindu, A., Beevi, N., L, M. and Benny, P.V. (2021) Public Perception and Preparedness for the Pandemic COVID-19: A Health Belief Model Approach. Clinical Epidemiology and Global Health, 9, 41-46. https://doi.org/10.1016/j.cegh.2020.06.009
[16]
Munung, N.S., Kamga, K.K., Treadwell, M.J., Dennis-Antwi, J., Anie, K.A., Bukini, D., et al. (2024) Perceptions and Preferences for Genetic Testing for Sickle Cell Disease or Trait: A Qualitative Study in Cameroon, Ghana and Tanzania. European Journal of Human Genetics, 32, 1307-1313. https://doi.org/10.1038/s41431-024-01553-7
[17]
Renjith, V., Yesodharan, R., Noronha, J.A., Ladd, E. and George, A. (2021) Qualitative Methods in Health Care Research. International Journal of Preventive Medicine, 12, 20. https://doi.org/10.4103/ijpvm.ijpvm_321_19
[18]
Bain, L.E., Akondeng, C., Njamnshi, W.Y., Mandi, H.E., Amu, H. and Njamnshi, A.K. (2022) Community Engagement in Research in Sub-Saharan Africa: Current Practices, Barriers, Facilitators, Ethical Considerations, and the Role of Gender—A Systematic Review. The Pan African Medical Journal, 43, Article 152. https://www.panafrican-med-journal.com//content/article/43/152/full
[19]
Tong, A., Sainsbury, P. and Craig, J. (2007) Consolidated Criteria for Reporting Qualitative Research (COREQ): A 32-Item Checklist for Interviews and Focus Groups. International Journal for Quality in Health Care, 19, 349-357. https://doi.org/10.1093/intqhc/mzm042
[20]
Burns, M., Bally, J., Burles, M., Holtslander, L. and Peacock, S. (2022) Constructivist Grounded Theory or Interpretive Phenomenology? Methodological Choices within Specific Study Contexts. International Journal of Qualitative Methods, 21, 1-13. https://doi.org/10.1177/16094069221077758
[21]
Campbell, K., Orr, E., Durepos, P., Nguyen, L., Li, L., Whitmore, C., et al. (2021) Reflexive Thematic Analysis for Applied Qualitative Health Research. The Qualitative Report, 26, 2011-2028. https://doi.org/10.46743/2160-3715/2021.5010
[22]
Becker, R., Chokoshvili, D., Thorogood, A., Dove, E.S., Molnár-Gábor, F., Ziaka, A., et al. (2024) Purpose Definition as a Crucial Step for Determining the Legal Basis under the GDPR: Implications for Scientific Research. Journal of Law and the Biosciences, 11, lsae001. https://doi.org/10.1093/jlb/lsae001
[23]
Patel, A. and Kuo, A. (2025) The Ethics of Gene Therapy for Sickle Cell Disease. Cureus, 17, e81037. https://doi.org/10.7759/cureus.81037
[24]
Minja, I.K., Nkya, S., Bukini, D., Mahenge, N., Masamu, U., Manongi, J., et al. (2025) Strengthening Global Partnerships for Sustainable Sickle Cell Disease Care: Insights from Sickleinafrica at the 77th United Nations General Assembly and the US-Africa Leaders’ Summit. BMJ Global Health, 10, e017154. https://doi.org/10.1136/bmjgh-2024-017154
[25]
Lappeman, J., Clark, R., Evans, J., Sierra-Rubia, L. and Gordon, P. (2020) Studying Social Media Sentiment Using Human Validated Analysis. MethodsX, 7, Article ID: 100867. https://doi.org/10.1016/j.mex.2020.100867
[26]
Massazza, A., Kienzler, H., Al-Mitwalli, S., Tamimi, N. and Giacaman, R. (2022) The Association between Uncertainty and Mental Health: A Scoping Review of the Quantitative Literature. Journal of Mental Health, 32, 480-491. https://doi.org/10.1080/09638237.2021.2022620
[27]
Dua, M., Bello-Manga, H., Carroll, Y.M., Galadanci, A.A., Ibrahim, U.A., King, A.A., et al. (2022) Strategies to Increase Access to Basic Sickle Cell Disease Care in Low-and Middle-Income Countries. Expert Review of Hematology, 15, 333-344. https://doi.org/10.1080/17474086.2022.2063116
